Answers are grounded in this paper and cite their sources.
We report a rare case of granulocyte colony-stimulating factor (G-CSF)-producing lung adenocarcinoma with a high PD-L1 expression and a KRAS G12V mutation that responded to pembrolizumab. A 72-year-old man presented with leukocytosis, elevated serum G-CSF levels, a diffuse bone marrow fluorodeoxyglucose uptake, and a rapidly progressive lung mass. A biopsy revealed TTF-1 positive adenocarcinoma with a PD-L1 tumor proportion score of 100 % and a KRAS G12V mutation. Pembrolizumab induced marked tumor regression and normalization of the G-CSF levels. However, immune-related pneumonitis resulted in treatment discontinuation. Pembrolizumab may be effective in selected patients with G-CSF-producing lung cancer despite its typically aggressive clinical behavior.
No takes yet. Share an insight, caveat, or question.
Arai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: